Introduction
============

Marshall Syndrome was first defined by Marshal in 1987^\[[@B1]\]^. The acronym FAPA (fever, aphthous stomatitis, pharyngitis, cervical adenitis) was was later renamed to PFAPA (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis)^\[[@B2]\]^. This clinical syndrome occurs among children less than 5 years old. It is a sporadic disease with periodic attacks of inflammation^\[[@B3]\]^. Periodic fevers usually last 3 to 6 days and occur with regular intervals about every 3 to 6 weeks. The diagnosis is established on the basis of clinical criteria that require the presence of a recurrent fever of early onset (\<5 years) and ≥1 of the 3 associated symptoms (aphthosis, cervical adenitis, and pharyngitis) in the absence of upper respiratory tract infections and cyclic neutropenia^\[[@B2]\]^.

Between episodes, the children usually are well.

The exact cause of PFAPA is unknown and autoimmune or infectious processes in its pathogenesis are not proven. Moreover no geographical or ethnic tendencies have been shown. WBC and ESR are increased during acute episodes^\[[@B4]\]^. Because a single dose of corticosteroid can resolve attacks, inflammatory cytokines production in response to infectious factors is considered as a leading cause of the syndrome. IFN-γ, TNF and IL-6 increase during episodes^\[[@B5],[@B6]\]^. It is more common in males and the prognosis is very good^\[[@B7],[@B8]\]^.

PFAPA has been reported in adult patients too^\[[@B9],[@B10]\]^. Although PFAPA is a periodic fever, no specific gene mutation is known for it. Nevertheless it is possible that genes involved in other inflammatory diseases play a role in its pathogenesis^\[[@B2]\]^.

In Cazeneuve's study among 12 allele analysis only one mutation of M694V was found^\[[@B11]\]^. Berkun study showed that in PFAPA patients with MEFV gene mutation the disease was less severe and aphthous stomatitis, duration of disease, number of attacks, and need to steroid were less common. Therefore they found MEFV gene effect as a modifier on PFAPA^\[[@B12]\]^.

In a study on 393 children with PFAPA, the clinical features were compared in genetically negative and positive results, 82 had positive genetic results, 75 uncertain and 236 negative results. Jn patients with positive genetic results diarrhea, vomiting, arthralgia and rash was more frequent. In the genetically negative group exudative pharyngitis was encountered more frequently^\[[@B13]\]^.

Gattorno et al evaluated the relationship between PFAPA and other periodic fevers such as FMF, MVK, and TRAPS. They found a close relationship between PFAPA and other periodic fever syndromes^\[[@B14]\]^.

FMF is an autosomal recessive disease characterized by acute attacks of fever and polyserositis. This disease mainly occurs in Mediterranean population and is caused by MEFV gene mutations^\[2\]^. This study was designed to analyse 12 most common MEFV gene mutations in PFAPA patients and also evaluating Gaslini score test based on detected mutations.

Subjects and Methods
====================

Twenty one patients who had diagnostic criteria were enrolled in this study. Twelve common MEFV gene mutations were evaluated: P369S, F479L, M680I(G/C), M680I(G/A), I692del, M694V, M694I, K695R, V726A, A744S, R761H, E148Q. All the patients were screened for 12 common MEFV mutations by a reverse hybridization assay (FMF StripAssay, Vienna lab, Vienna, Austria) according to the instructions provided by the manufacturer. Statistical analysis was performed using SPSS 16.0. Comparison between the different genotypes was assessed using chi-square test. A *P*-value \<0.05 was accepted as statistically significant.

Findings
========

The age of patients was between 6 months and 14 years, and 15 were males. The mean age at onset of symptoms was 1.52±2.72 years (range 6 months - 5 years). The mean duration of fever was 3.57±1.64 days, and that of the disease 4.23±1.56 days. The interval of the attacks was 32.52±20.53 days. All of the patients had fever and 12 (57.14%) patients had abdominal pain, 19 (90.47%) children were breast fed infants.

In family history one patient\'s brother, one patient\'s father and one patient\'s mother had FMF. Eight (38.09%) patients had MEFV gene mutations, seven of them were heterozygotes and one was combined heterozygous (K695R, V725A).

([Table 1](#T1){ref-type="table"}).

Although abdominal pain, aphthous stomatitis and duration of attacks were more common in non-mutated patients, these findings in association with episodes of fever and response to treatment did not show meaningful difference between the two groups (*P*≤0.05).

###### 

Prevalence of MEFV gene mutations

  --------------- ---------------- -------------
  **MEFV Gene**   **Prevalence**   **Percent**
  **M694V**       4                45
  **V726A**       3                33
  **K694R**       1                11
  **E148Q**       1                11
  --------------- ---------------- -------------

###### 

Clinical findings in different studies

  --------------------------- ---------------- ---------------------------------- ---------------------------------- ------------------------------ ----------------------------
  **Signs and symptoms**      **Our study**\   **Gattorno** ^\[^ ^[@B14]^ ^\]^\   **Stojanov** ^\[^ ^[@B15]^ ^\]^\   **Padeh** ^\[^ ^[@B8]^ ^\]^\   **Dagan\[** ^[@B16]^ ^\]^\
                              **%**            **%**                              **%**                              **%**                          **%**

  **Fever**                   100              \--                                78                                 100                            \--

  **Weakness and lethargy**   71.42            \--                                \--                                100                            \--

  **Skin rash**               14.28            24                                 18                                 \--                            \--

  **Headache**                28.6             46                                 6.5                                17.8                           \--

  **Oral aphthosis**          47.61            63                                 13                                 67.8                           33.3

  **Abdominal pain**          57.14            68                                 42                                 17.8                           35.1

  **Myalgia**                 61.9             3.5                                \--                                \--                            \--

  **Diarrhea**                \--              36                                 \--                                \--                            \--

  **Vomiting**                \--              41                                 \--                                \--                            \--

  **Arthralgia**              13               49                                 \--                                10.7                           \--
  --------------------------- ---------------- ---------------------------------- ---------------------------------- ------------------------------ ----------------------------

Discussion
==========

Padeh^\[[@B8]\]^, Stojanov ^\[[@B15]\]^ and Dagan ^\[[@B16]\]^ studies in comparison with our results are shown in [Table 2](#T2){ref-type="table"}. [Table 3](#T3){ref-type="table"} shows our results and those of Gattornos.

Bonyadi revealed that the carrier rate of five common MEFV genes in the Azeri Turkish population was 25.5%, with E148Q being the most common (11.5%) mutation followed by V726A (1.75%). This study indicates that the FMF carrier rate and E148Q mutation frequency are high in the Iranian Azeri Turkish population^\[[@B17]\]^ and one of our studies showed the frequency of E148Q mutation in FMF patients to be 9.95% (in press). It does not seem that these MEFV mutations in PFAPA patients are related to normal population varieties.

The authors have known two siblings suffering from FMF with M694V -- V726A gene mutation, and PFAPA syndrome, offspring of whom one had monozygotic mutation M694V and the other monozygotic mutation V726A.

In other authors' experience there were 2 patients who had FMF and PFAPA simultaneously, it was observed that the first patient had R761H-M694I combined mutations and the second one M680I monozygotic mutation.

It seems that there is a genetic similarity, on the basis of pathogenesis, between FMF and PFAPA. This genetic similarity has led to suggest a scoring system in genetic analysis of periodic fever syndromes in PFAPA patients^\[[@B13]\]^.

###### 

MEFV genes mutations in two studies

  --------------------------------------------------------------------
  **Heterozygote**                  **Our study**   **Gattorno(14)**
  ------------------ -------------- --------------- ------------------
  **Compound**\      Number         1               7
  **Heterozygote**                                  

  Type of Mutation   K695R/ V726A   M694V/V726A\    
                                    M680I/V726A\    
                                    M694V/E148Q\    
                                    L110P/L110P\    
                                    V726A/E148Q\    
                                    V726A/S108R\    
                                    P369S/R408Q     

  **Heterozygote**   Number         7               33

  Type of Mutation   M694V (4)\     E148Q (11)\     
                     V726A (2)\     K695R (5)\      
                     E148Q (1)      M694V (4)\      
                                    A744S (3)\      
                                    V726A (2)\      
                                    P369S (1)\      
                                    V487M (1)\      
                                    R408Q (1)\      
                                    M680I (1)\      
                                    R717L (1)       
  --------------------------------------------------------------------

###### 

Gaslini score in our patients

  -------- --------- --------- ------------- ---------- -------------- ------------ ---------------- -------------- ---------------- --------------
  **No**   **Age**   **Sex**   **Age at**\   **Abd**\   **Diarrhea**   **Chest**\   **Aphtous**\     **Genotype**   **Family**\      **Gaslini**\
                               **Onset**     **pain**                  **pain**     **stomatitis**                  **history**      **score**

  1        5         Boy       2y            Yes        No             No           No               Wt- Wt         No               -0.027

  2        7         Boy       3y            Yes        Yes            No           Yes              Wt-M694V       No               +1.38

  3        5         Boy       2y            No         No             No           No               Wt- Wt         No               -1.608

  4        13        Girl      6 mo          Yes        No             No           Yes              Wt- Wt         No               +1.082

  5        6         Boy       4y            Yes        No             No           No               Wt- Wt         No               -0.228

  6        7         Boy       6y            Yes        No             No           Yes              Wt- Wt         No               -3.34

  7        4         Girl      2y            Yes        No             No           Yes              Wt- Wt         No               -0.124

  8        5         Boy       3y            No         No             No           No               Wt- Wt         No               -2.412

  9        5         Girl      1y            No         No             No           Yes              Wt-V726A       Father: FMF      -0.802

  10       5         Boy       10 mo         No         No             No           No               Wt- Wt         No               -0.67

  11       12        Boy       2y            No         No             No           Yes              Wt- Wt         No               -3.112

  12       12        Boy       3y            No         No             No           No               Wt-M694V       No               -2.412

  13       12        Boy       2y            Yes        No             No           Yes              Wt- Wt         Brother:\        +1.379
                                                                                                                    Periodic Fever   

  14       4         Boy       6 mo          Yes        No             No           Yes              Wt- Wt         No               +1.082

  15       14        Girl      6y            Yes        No             No           No               Wt-E148Q       No               -1.836

  16       9         Boy       3y            No         No             No           Yes              Wt- Wt         No               -3.916

  17       10        Boy       5y            Yes        No             No           Yes              Wt-M694V       No               -2.536

  18       13        Boy       5y            No         No             No           Yes              K695R-V726A    No               -5.524

  19       8         Boy       2y            No         No             No           Yes              Wt-M694V       No               -3.112

  20       7         Girl      3y            Yes        No             No           Yes              Wt-V726A       Mother: FMF      +0.575

  21       8         Girl      3y            Yes        No             No           Yes              Wt- Wt         No               -0.928
  -------- --------- --------- ------------- ---------- -------------- ------------ ---------------- -------------- ---------------- --------------

This scoring is based on clinical criteria and is called Gaslini diagnostic score. If a PFAPA patient has scored above 1.32, he/she will be in a high risk of having others periodic fever syndromes.

In Gattorno study it was observed that Gaslini diagnostic score is a useful diagnostic tool in evaluating differential diagnosis of PFAPA syndrome.

Because 38 percent of PFAPA patients in this study had MEFV gene mutations, it seems that genetic basis of FMF has a role in pathogenesis of PFAPA; however there is no significant difference between mutation positive and negative patients in duration of disease, episodes of disease and response to treatment. [Table 4](#T4){ref-type="table"} shows patients' Gaslini diagnostic scoring test.

Conclusion
==========

This scoring was not helpful to predict the probability of MEFV gene mutation (12 common mutations) in our study and in these patients it has also been shown that MEFV gene mutation doesn\'t have any specific effect in patient's clinical manifestations. We should find another way to predict the presence of MEFV gene mutations in this syndrome.
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